Search Results

TwinStrand Biosciences®, the pioneer in Duplex Sequencing technology, which delivers accurate insights to researchers in applications ranging from genetic toxicology to residual cancer detection announces the successful acceptance of the standard project submission form (SPSF) by the Organization for Economic Cooperation and Development (OECD).

TwinStrand Biosciences®, the pioneer in Duplex Sequencing technology, which delivers accurate insights to researchers in applications ranging from residual cancer detection to genetic toxicology announced the appointment of Ron Andrews, as Chief Executive Officer and Board Member.

TwinStrand Biosciences, Inc. today announced that the company has implemented a reorganization designed to sustain growth through a focus on key commercial initiatives.

TwinStrand Biosciences, Inc. today announced the appointment of Goran Pljevaljcic, Ph.D. as Chief Commercial Officer.

Singular Genomics Systems Inc. and TwinStrand Biosciences, Inc. announced a collaboration to develop highly sensitive next generation sequencing solutions for the Singular G4 Sequencing Platform for cutting-edge applications like minimal residual disease detection.

Staff cuts will leave IGM Biosciences with 37 employees. The company is also halting development of two bispecific antibody T cell engagers for autoimmune diseases.

TwinStrand Biosciences announced it has entered into a worldwide non-exclusive agreement to sublicense two foundational patent families to Foundation Medicine and its affiliates relating to TwinStrand Duplex Sequencing™ error-correction technology.